Skip to main content

Advertisement

Fig. 3 | Clinical Epigenetics

Fig. 3

From: Epigenetic silencing of MEIS2 in prostate cancer recurrence

Fig. 3

DNA methylation and transcriptional expression of MEIS2 in the discovery and TCGA cohorts. a Left: Mean DNA methylation across the MEIS2 gene in the discovery cohort (27 PC (black)/15 AN (gray) samples. 450K). Right: Zoom in on promoter region of MEIS2 (green-box in left plot). b DNA methylation of cg06933370 and cg25381383 in the discovery cohort (27 PC/15 AN samples from 450K). c MEIS2 RNA expression in the discovery cohort (22 PC/12 AN samples. RNAseq). d Spearman's correlation between  DNA methylation of cg06933370 (covered by qMSP assay 1, see Fig. a) or cg25381383 (covered by qMSP assay 2, see a) and MEIS2 RNA expression in the discovery cohort (22 PC (black)/12 AN samples (gray)). e DNA methylation of cg06933370 and cg25381383 in the TCGA cohort (497 PC/36 AN samples. 450K). f MEIS2 expression in the TCGA cohort (495 PC/52 AN samples; RNAseq). g Correlation between DNA methylation of cg06933370 or cg25381383 and MEIS2 RNA expression in TCGA data (495 PC (black)/36 AN (gray)). PC, prostate cancer; AN, adjacent normal; CPM, counts per million; Chr., chromosome; BH adj., Benjamini-Hochberg adjusted; P, p value

Back to article page